Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Royal Marsden NHS Foundation Trust
With
Institute of Cancer Research, United Kingdom
FR may be released from the cancer cells in the blood. We have developed a method in the laboratory which has been able to measure the FR obtained from cancer cells in culture which has been added into blood. We would like to study if this method is able to measure the FR in stored plasma samples obtained from patients with ovarian cancer, so that it may be developed as a method for selecting patients for FR-target treatments such as BGC 945.
Age
Any age
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with ovarian cancer who have given informed consent to have blood collected for the plasma bank in the 'Pharmacogenetics and proteomics studies in patients receiving novel anticaner agents' study.
You may not be if
Patients who have withdrawn consent form their blood stored within the 'Pharmacogenetics and proteomics studies in patients receiving novel anticancer agents' study to be used for research.
